Back to search results

Methamphetamine Use Disorder and Contingency Management Study

This study is looking at how reduced methamphetamine use can benefit people with Methamphetamine Use Disorder. It's testing a behavioral intervention called Contingency Management, where you receive payments for providing urine samples that are negative for methamphetamine. To join, you need to be at least 18 years old, have used methamphetamine recently, and meet the criteria for moderate-to-severe Methamphetamine Use Disorder. The researchers will measure changes in your Mean Arterial Pressure (blood pressure) at the start and during the first two weeks of the study to see if reduced use has positive health impacts. The study aims to enroll 300 participants, but its current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 300 participants. It is not specified if it is randomized or blinded.
What's involved
You would commit to a 12-week intervention. This involves providing methamphetamine-negative urine samples.
Compensation
Subjects will receive payments for providing methamphetamine negative urine samples.
Follow-up
Mean Arterial Pressure will be measured at baseline, Week 1, and Week 2 of participation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07226596

Non-Abstinence Outcomes in Methamphetamine Use Disorder

Recruiting
NAAges 18+InterventionalBasic science
William Stoops
~300 participants
Updated 2026-06-08 on ClinicalTrials.gov
What's tested:Contingency Management

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean Arterial Pressure
Measured over At baseline.
+16 more outcomes measured

Conditions

Methamphetamine Use Disorder

Explore related trials

Amphetamine-induced organic mental disorder

NCT07226596

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Psychopharmacology of Addiction Laboratory

    Lexington, Kentuckystudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • William W Stoops, PhD · PRINCIPAL_INVESTIGATOR · University of Kentucky

Who to contact

William W Stoops, PhD
[email protected]
8592575388
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

be age 18 years or older;
self-report methamphetamine use in the week prior to screening;
provide a methamphetamine-positive urine sample at screening;
meet DSM-5 criteria for moderate-severe Methamphetamine Use Disorder (MUD);
be seeking treatment for their methamphetamine use
be able and willing to commit to the 12-week intervention, as well as the 12-week post-intervention follow-up
Individuals who meet these criteria and are stably maintained on buprenorphine or methadone for Opioid Use Disorder (OUD) will also be eligible to participate.

Exclusion

current or past medical or psychiatric illness (e.g., physical dependence on any drug other than buprenorphine requiring medically managed detoxification, unstable angina, uncontrolled cardiac arrhythmia, aortic stenosis, self-reported compromised immune function, severe diagnosis for a SUD other than MUD or treated OUD) that would interfere with study participation in the opinion of the study physicians
poor venous access precluding blood draws

What this trial measures

  • Mean Arterial PressureAt baseline.

    Mean Arterial Pressure is recorded during subject visits and is recorded in mm Hg

  • Mean Arterial PressureWeek 1 of participation.

    Mean Arterial Pressure is recorded during subject visits and is recorded in mm Hg

  • Mean Arterial PressureWeek 2 of participation.

    Mean Arterial Pressure is recorded during subject visits and is recorded in mm Hg

  • Mean Arterial PressureWeek 3 of participation.

    Mean Arterial Pressure is recorded during subject visits and is recorded in mm Hg

  • Mean Arterial PressureWeek 4 of participation.

    Mean Arterial Pressure is recorded during subject visits and is recorded in mm Hg

  • Mean Arterial PressureWeek 5 of participation.

    Mean Arterial Pressure is recorded during subject visits and is recorded in mm Hg

  • Mean Arterial PressureWeek 6 of participation.

    Mean Arterial Pressure is recorded during subject visits and is recorded in mm Hg

  • Mean Arterial PressureWeek 7 of participation.

    Mean Arterial Pressure is recorded during subject visits and is recorded in mm Hg

  • Mean Arterial PressureWeek 8 of participation.

    Mean Arterial Pressure was recorded during subject visits and is recorded in mm Hg

  • Mean Arterial PressureWeek 8 of participation.

    Mean Arterial Pressure is recorded during subject visits and is recorded in mm Hg

  • Mean Arterial PressureWeek 9 of participation.

    Mean Arterial Pressure is recorded during subject visits and is recorded in mm Hg

  • Mean Arterial PressureWeek 10 of participation.

    Mean Arterial Pressure is recorded during subject visits and is recorded in mm Hg

  • Mean Arterial PressureWeek 11 of participation.

    Mean Arterial Pressure is recorded during subject visits and is recorded in mm Hg

  • Mean Arterial PressureWeek 12 of participation.

    Mean Arterial Pressure is recorded during subject visits and is recorded in mm Hg

  • Endothelin-1At baseline.

    Endothelin-1 levels will be measured. They will be recorded in pg/ml.

  • Endothelin-1Week 6 of participation.

    Endothelin-1 levels will be measured. They will be recorded in pg/ml.

  • Endothelin-1Week 12 of participation.

    Endothelin-1 levels will be measured. They will be recorded in pg/ml.